Dr. Reddy’s ka Dimaag Charkha!
Wah! Dr. Reddy’s Laboratories ne fourth quarter mein kamaal kar dikhaaya hai! Unka net profit 22% badh gaya hai, jo ki analysts ke expectations se bhi zyada hai. March 2025 mein khatam huye quarter mein, unhone Rs 1,593 crore ka profit banaya. Bloomberg ke analysts to sirf Rs 1,459 crore ka hi andaza laga rahe the!
Numbers ki Baatein
Chaliye, thodi aur details dekhte hain. Unka revenue 20% badhkar Rs 8,528 crore hogaya hai (Bloomberg estimate tha Rs 8,359.7 crore). Ebitda bhi 13.3% badhkar Rs 2,074.7 crore par pahunch gaya (estimate tha Rs 2,268.6 crore). Margin thoda sa kam hua hai, 26.4% se girkar 24.3% par (estimate tha 27.1%). Lekin overall, yeh ek bada success hai!
Global Markets mein Dangal!
Dr. Reddy’s ka global generics business bhi jhakkas chal raha hai. Revenue 23% badha hai saal-dar-saal! North America mein bhi achcha growth hai, 9% saal-dar-saal aur 5% quarter-dar-quarter. Europe mein to kamaal hi kar dikhaaya hai, 145% ki badhotari! India aur Emerging Markets mein bhi growth hai, par thoda sa kam.
Management kya keh rahe hain?
Managing Director GV Prasad ne kaha, “Humne apne sabhi businesses mein double-digit growth achieve kiya hai. Yeh sab successful product launches, US mein key products se zyada revenue, aur acquired NRT business ke integration ki wajah se hua hai.” Unhone aage yeh bhi kaha ki woh apne core businesses ko aur strong banane par focus karenge.
Stock Market mein Teji!
Yeh sab news sunke Dr. Reddy’s ke shares bhi ud gaye! BSE par 0.67% ki badhotari hui, jabki Sensex 1.1% gira hai. Toh yeh thi Dr. Reddy’s ki kamaal ki success story!
